Albert Einstein College of Medicine (Wakefield Campus) Internal Medicine

Topics

• Acute Myeloid Leukemia Research 41
• COVID-19 Clinical Research Studies 20
• Ocular Diseases and Behçet’s Syndrome 18
• Coronary Interventions and Diagnostics 17
• Lung Cancer Treatments and Mutations 17
• Intensive Care Unit Cognitive Disorders 16
• Mechanical Circulatory Support Devices 16
• Renal cell carcinoma treatment 16
• Heart Failure Treatment and Management 15
• Atrial Fibrillation Management and Outcomes 14
• Acute Kidney Injury Research 13
• Balance, Gait, and Falls Prevention 13

Most cited

1. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women.

   The New England journal of medicine · 2021 · 889 citations · Diana Pinzon

2. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.

   The New England journal of medicine · 2024 · 409 citations · Mahadi Baig

3. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.

   The New England journal of medicine · 2025 · 114 citations · Mahadi Baig

4. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 256 citations · Diana Pinzon

5. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence.

   Cancers · 2023 · 153 citations · Yiquing Xu

6. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.

   Hepatology (Baltimore, Md.) · 2021 · 250 citations · Bal Bhandari

7. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.